Samsung Biologics Internalizes MCB, Vector Services to Boost End-to-End CDO

(Source=Samsung Biologics) [Song Young Doo, Edaily Reporter] Samsung Biologics is moving to strengthen its contract development(CDO) competitiveness by internalizing key service capabilities.

The company announced on March 23 that it has internalized master cell bank(MCB) production and vector construction services within its CDO portfolio, and hosted a webinar to mark the launch.

The company also presented a development timeline that enables completion of the entire process, from vector construction to Investigational New Drug(IND) submission, within nine months, highlighting its capability to deliver optimized end-to-end services.